Antibody Based Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antibody-based therapies for neurodegenerative diseases represent one of the most active areas of drug development, with multiple FDA approvals in Alzheimer's disease and numerous candidates in clinical trials for Parkinson's, ALS, and other conditions. These therapies employ monoclonal antibodies to target pathological proteins, modulate neuroinflammation, or deliver therapeutic payloads to the brain.
The most advanced area of antibody therapy, targeting amyloid-beta in Alzheimer's disease:
| Antibody | Target | Company | Status | Mechanism |
|---|---|---|---|---|
| Lecanemab | Aβ protofibrils | Eisai/Biogen | FDA Approved (2023) | Clears soluble Aβ |
| Donanemab | N-terminal Aβ | Eli Lilly | FDA Approved (2024) | Plaque reduction |
| Aducanumab | Aβ plaques | Biogen | FDA Approved (2021) | Amyloid removal |
| Gantenerumab | Aβ plaques | Roche | Withdrawn | Plaque clearance |
| Crenezumab | Oligomeric Aβ | Roche | Discontinued | Oligomer neutralization |
| Solanezumab | Mid-domain Aβ | Eli Lilly | Discontinued | Monomer clearance |
Targeting tau pathology, often combined with anti-amyloid approaches:
| Antibody | Target | Company | Status | Notes |
|---|---|---|---|---|
| Semorinemab | Tau oligomers | Genentech | Phase II | Motor tau reduction |
| Tilavonemab | Tau | AbbVie | Phase II | N-terminal tau |
| Bepranemab | Tau | UCB | Phase II | Mid-region tau |
| JNJ-63733657 | Tau | Janssen | Phase I | Phospho-tau specific |
Targeting α-synuclein for Parkinson's and related disorders:
| Antibody | Target | Company | Status | Notes |
|---|---|---|---|---|
| Prasinezumab | α-Syn | Roche | Phase II | Reduced progression |
| Cinpanemab | α-Syn | Biogen | Phase II | Discontinued |
| ABBV-0805 | α-Syn | AbbVie | Phase I | α-syn targeting |
| Antibody | Target | Company | Status | Notes |
|---|---|---|---|---|
| Tominersen | HTT mRNA | Roche | Discontinued | ASO, not antibody |
Targeting microglial activation and inflammatory pathways:
| Antibody | Target | Company | Status | Notes |
|---|---|---|---|---|
| AL003 | TREM2 | Alector | Phase II | Microglia activation |
| AL002 | TREM2 | Alector/AbbVie | Phase II | TREM2 agonism |
| Semorinemab | Tau | See above | Phase II | - |
| Antibody | Target | Company | Status | Notes |
|---|---|---|---|---|
| Anti-BDNF | BDNF | Various | Pre-clinical | Neutralizes inhibitory BDNF |
The study of Antibody Based Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and progress. Alzheimers Dement. 2024;20(1):285-301.
[2] Sims JR, Zimmer JA, Evans CD, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
[3] Swarup V, Dzahini O, Huang Y, et al. Anti-tau antibody therapy for Alzheimer's disease: progress and challenges. Mol Psychiatry. 2023;28(12):5044-5058.
[4] Pagano M, Taylor KI, Enzinger C, et of prasinezumab in Parkinson's disease. N Engl J Med. 2024;390(9):785-794.
[5] Masliah E, Rockenstein E, Veinbergs I, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. Proc Natl Acad Sci. 2001;98(24):13681-13686.
[6] Cumulative summary of anti-amyloid antibodies in clinical trials for Alzheimer's disease. Nat Rev Drug Discov. 2024;23(3):181-200.
[7] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2024;404(10452):932-946.
[8] Hampel H, Hardy J, Blennow K, et al. The amyloid-beta cascade hypothesis: ten years later. Alzheimers Dement. 2024;20(1):e2023065967.